Metabolism in Organoids and 3D Culture: The Gradient Is the Finding, and It Is Usually Unreported
The thesis
Three-dimensional culture changes a metabolic question rather than refining it. In a monolayer, the question is what a cell does. In an organoid, the question is what a tissue does — and a tissue is defined by the fact that its cells experience different conditions.
First, the gradient arrives with the geometry. Oxygen penetrates 100–200 µm before consumption depletes it. Beyond a few hundred microns, an organoid has a proliferating rim, a quiescent zone and a core that is hypoxic or dead. Every bulk measurement is an average over that structure.
Second, the structure is the interesting part. Zonation — regional differences in metabolism within a tissue — exists in liver, kidney and intestine, and organoids were expected to reproduce it. Some do, partially. Reporting it requires resolving zones, which bulk measurements cannot do.
Third, the culture variables are larger than the treatment effects. Size, day, matrix batch, medium refresh rate and oxygen all change the metabolic state. A treatment that alters any of them looks like a metabolic effect.
Three levels
| Level | Claim | Minimum evidence | What does not count |
|---|---|---|---|
| ① Gradient | A gradient exists in the organoid | Size-matched organoids, a validated reporter or sectioning | A hypoxic-core image without size data |
| ② Zonation | Zones differ in metabolism, not only in oxygen | Per-zone measurement, or a zone-specific marker with a metabolic readout | A bulk average compared with a 2D control |
| ③ Function | The zonation is required for the tissue phenotype | Perturbation that removes the gradient, with the phenotype | Correlation between zone and marker |
Most organoid metabolic papers are level zero: a bulk measurement of an uncharacterised structure. Level one is achievable with modest effort and is rarely done.
Important distinction. Level two is not implied by level one. A hypoxic core proves that oxygen differs; it does not prove that metabolism differs in a way that matters, because a cell can maintain flux by switching substrate without changing its measurable output.
The variables that decide the answer
| Variable | Effect | Reported? |
|---|---|---|
| Diameter and its distribution | Determines necrotic fraction | Usually as a mean |
| Day of culture | Matrix deposition, lumen formation, differentiation | Sometimes |
| Medium refresh rate | Creates a feeding cycle; entrains metabolism | Rarely |
| Matrix (Matrigel or equivalent) | Protein and lipid source; binds drugs and metabolites | Rarely quantified |
| Oxygen tension | Sets the baseline gradient | Often assumed to be 21% |
| Absence of vasculature | Fixes the diffusion limit | Stated as a limitation, not as a variable |
| Absence of systemic hormones | Changes differentiation and substrate handling | Rarely discussed |
Two entries deserve emphasis. Matrigel is not inert: it is a complex protein mixture, it contributes amino acids and can bind small molecules, and its batch variability is a known source of irreproducibility. Medium refresh imposes a cycle: fresh medium at day 0, depletion by day 3, with a metabolite profile that reflects the feeding schedule as much as the tissue.
What the geometry makes impossible
- • Absolute rate per cell. The bulk value is an average over cells with different fluxes.
- • A clean comparison with 2D. Cell number, nutrient access and proliferation differ simultaneously.
- • Dose–response for a drug. Penetration is a variable, so the cells experience a concentration gradient, not a concentration.
- • "Microenvironment" claims. There is no vasculature, no immune compartment and no innervation. What exists is a diffusion gradient and a matrix.
Caveat on the word "organoid". An organoid is self-organised and contains multiple cell types; a spheroid is a cluster, often of one line. The metabolic consequences differ, because a spheroid has no epithelial polarisation and no lumen. Using the terms interchangeably makes the comparison across papers meaningless.
What the field can support now
- • Penetration and diffusion questions, where the gradient is the subject rather than a nuisance.
- • Drug response under a gradient, with the gradient reported.
- • Maturation effects on metabolic capacity, if size and day are controlled and stated.
- • Comparisons between organoid lines, provided the size distribution and matrix batch are matched.
What it cannot support yet
- • Absolute metabolic rates per cell or per tissue.
- • A claim that a pathway is required, without a per-zone measurement or a genetic perturbation.
- • Translation to patient response, because the diffusion limit is not the patient's diffusion limit.
Three predictions, each with its refutation
- Size distribution and day will become mandatory reporting items, in the way that antibody validation became mandatory. Refuted if multi-laboratory datasets show metabolic readouts are insensitive to size within the working range.
- Per-zone methods — sectioning, spatial metabolomics, zone-specific reporters — will replace bulk measurement for any claim about zonation. Refuted if bulk values are shown to predict per-zone values across conditions.
- Organoid metabolic screens will not translate to patients until the diffusion limit is included in the analysis. Refuted if a screen validated only in organoids predicts clinical response.
These are methodological claims about a model system, not statements about any therapeutic.
The practical correction
Four items, each cheap, would remove most of the current ambiguity:
- Report the size distribution, not the mean, with the day of assay.
- Report the medium refresh schedule, and sample metabolites at a defined point in the cycle.
- Report the matrix lot and whether it was tested for metabolite binding.
- State whether the claim is about the average or about a zone, and choose the method accordingly.
The fourth item is the one that changes the writing. A paper that says "organoid metabolism shifted toward glycolysis" is making an average claim and should say so. A paper that says "the core is glycolytic and the rim is oxidative" is making a zonal claim and needs a zonal method.
Readout note. Where a bulk measurement is unavoidable, a size-matched 2D control at the same cell number is the minimum comparison, and the difference between them is partly geometry. Reporting the difference as "3D reprogramming" attributes a diffusion effect to the cells.
Where this connects
- • Mitochondrial pillar supplies the hypoxia and substrate-switching logic that the gradient imposes.
- • Tumour spheroid work supplies the operational parameters — seeding, size control, dissociation bias — for the model this article discusses conceptually.
- • Disease pillar supplies the model-tier frame: a 3D system adds geometry and cell–cell contact, not a vasculature or an immune compartment.
Scientific interpretation and experimental design
- • The gradient is the model, not a confound — but it must be measured.
- • Report size distribution and day.
- • Match sizes between conditions.
- • State the refresh schedule.
- • Treat the matrix as a reagent with a lot number.
- • Bulk values are averages; write the claim accordingly.
- • Do not call a gradient a microenvironment.
Selected references for further reading
- • Sato T, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–265.
- • Riffle S, Hegde RS. Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids. Journal of Experimental & Clinical Cancer Research. 2017;36:102.
- • Place TL, Domann FE, Case AJ. Limitations of oxygen delivery to cells in culture: an underappreciated problem in basic and translational research. Free Radical Biology and Medicine. 2017;113:311–322.
- • Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010;10:1886–1890.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »